Johnson & Johnson‘s Vision business said last week that it inked a deal to acquire ophthalmalogical medical device maker TearScience for an undisclosed amount.
Resarch Triangle Park, N.C.-based TearScience produces devices focused on treating meibomian gland dysfunction, a leading underlying cause of dry eye disease, Johnson & Johnson said.
TearScience has won FDA clearance for its office-based treatment of meibomian glands and treating MGD, with its devices available in the US and global markets, the company said.
“Dry eye is a significant unmet health need globally, and meibomian gland dysfunction is the cause for more than 60% of people living with this condition. The innovative portfolio from TearScience positively impacts the lives of patients around the world suffering from this chronic condition. These solutions, coupled with our existing contact lens and surgical portfolio, will allow us to help more patients with their vision needs, throughout their lifetime,” J&J Vision companies group chair Ashley McEvoy said in a press release.
Johnson & Johnson said the acquisition will be through its recently acquired Abbott Medical Optics division, and that it expects the acquisition to close by the end of the year.
Last month, J&J said its medical device division is rolling its Pulsar Vascular and Neuravi acquisitions, as well as its existing Codman Neuro neurological portfolio, into a new neurovascular business dubbed Cerenovus.
By Fink Densford
Source: Mass Device
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
